<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505764</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-013-08F</org_study_id>
    <secondary_id>HT-ANAM-208</secondary_id>
    <nct_id>NCT01505764</nct_id>
  </id_info>
  <brief_title>The Role of Ghrelin in Cancer Cachexia</brief_title>
  <official_title>The Role of Ghrelin in Cancer Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinn Therapeutics (U.S.), Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer is often coupled with a condition called cachexia. In this condition, individuals
      continue to lose weight and lean body mass, which means their muscles are getting smaller and
      weaker. Studies have shown that cancer patients who are losing weight often are responding
      poorly to chemotherapy, are at greater risk of infection and have a reduced life expectancy.
      Also, people may not want to eat. To date, there are no approved treatments available for
      this condition.

      This study is going to study the benefits of the use of the study drug, Anamorelin
      hydrochloride (HCl) in treatment or prevention of cachexia associated with cancer. Studies
      done before with the study drug have shown that the drug can help the cachectic condition.
      The purpose of this research study is to evaluate the effectiveness of Anamorelin HCl
      compared to placebo on body composition (amount of cell mass, fat, muscle, etc.) including
      measurements of body potassium and nitrogen stores.

      In addition to the above, the study will also assess the effect of the study drug on handgrip
      strength, body weight, lean muscle mass, quality of life, appetite &amp; food intake, certain
      blood markers, energy expenditure (the amount of energy participants burn), functional
      performance, safety and tolerability of Anamorelin HCl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in the study will be randomly chosen to receive either Anamorelin HCL at a
      dose of 100 mg per day for 12 weeks or matching placebo. The chances of receiving anamorelin
      or placebo are 1 in 2. Which subject receives anamorelin or placebo will be decided at
      random. Neither the subject nor the study doctor will know which study drug the subject is
      receiving. The subject will be asked to visit the clinic at Day 1, Day 28, Day 56 and Day 84.
      There will also be a Day 112 follow-up visit and the medical records will be checked after
      that to see how the subjects are doing.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Body Potassium.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Composition as Measured by Densitometry.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength as Measured by Grip Strength.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life.</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life as assessed using the Assessment SpondyloArthritis (ASAS), EuroQol five dimensions questionnaire (EQ-5D) and FACIT-F, Patient Reported Outcome assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite.</measure>
    <time_frame>2 years</time_frame>
    <description>Appetite measured by a visual analogue scale and a food diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Energy Expenditure.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Performance.</measure>
    <time_frame>2 years</time_frame>
    <description>Functional performance using stair-climbing power, 6-minute walk, tests of the major muscle groups and 24 hour physical activity levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition.</measure>
    <time_frame>2 years</time_frame>
    <description>Body composition as measured by Total body nitrogen and bioimpedance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability.</measure>
    <time_frame>2 years</time_frame>
    <description>The safety and tolerability of Anamorelin HCl assessed through the number of participants with Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cancer Cachexia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anamorelin HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anamorelin HCl</intervention_name>
    <description>100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have incurable, histologically or cytologically documented Non-Small Cell Lung
             Cancer or Colo-rectal Cancer.

          -  Females and males at least 18 years of age.

          -  Documented histologic or cytologic diagnosis of American Joint Committee on Cancer
             (AJCC) unresectable Stage III or IV NSCLC and/or stage III or IV colorectal cancer
             (CRC) (not amenable to curative resection).

          -  Involuntary weight loss of 5% body weight over a period of 6 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 2 at screening.

          -  Estimated life expectancy of greater than 4 months at the time of screening.

          -  Presence and functional use of both hands.

          -  Able to understand and comply with the procedures of the handgrip strength evaluation.

          -  If the patient is a woman of childbearing potential or a fertile man, he/she must
             agree to use an effective form of contraception during the study and for 28 days
             following the last dose of study medication.

          -  Willing and able to give signed informed consent and, in the opinion of the
             Investigator, to comply with the protocol tests and procedures.

        Exclusion Criteria:

          -  Other forms of lung cancer.

          -  Women who are pregnant or breast-feeding.

          -  Obesity.

          -  Recent active excessive alcohol or illicit drug use current use of marijuana or
             history of marijuana use over the previous 6 months.

          -  Severe depression.

          -  Other causes of cachexia such as:

               -  Liver disease (AST or ALT &gt; 3x normal levels)

               -  Renal failure (creatinine &gt; 2.5 mg/dL)

               -  Untreated thyroid disease

               -  Class III-IV CHF

               -  AIDS

               -  Other cancer diagnosed within the past five years other than non-melanoma skin
                  cancer and prostate cancer

               -  Severe COPD requiring use of home O2.

          -  Inability to increase food intake.

          -  Recent administration of highly emetogenic chemotherapy.

          -  Known HIV, active hepatitis B or C (with increased LFTs), or active tuberculosis.

          -  Patients who have received two prior regimens of cytotoxic chemotherapy and are
             undergoing, or planning to undergo, a third regimen of cytotoxic chemotherapy.

          -  Currently taking prescription medications intended to increase appetite or treat
             weight loss; these include, but are not limited to:

               -  Testosterone

               -  Androgenic compounds

               -  Megestrol acetate

               -  Methylphenidate

               -  Dronabinol

          -  Current use of steroids or history of use over the previous 6 months except as pre-
             and post-medications for chemotherapy administration.

          -  Patients unable to readily swallow oral tablets.

          -  An active, uncontrolled infection.

          -  Uncontrolled diabetes mellitus.

          -  Known or suspected brain metastases.

          -  Patients receiving strong CYP3A4 inhibitors.

          -  Patients receiving tube feedings or parenteral nutrition.

          -  Patients with any concomitant medical or psychiatric condition or social situation
             that would make it difficult to comply with protocol requirements, including the
             inability to comply with handgrip strength determinations in both hands; for example,
             pre-existing neurological impairment.

          -  Previous exposure to Anamorelin HCl.

          -  Patients actively receiving a concurrent investigational agent, or any patients that
             have received an investigational agent within four weeks prior to randomization.

          -  Current use of diuretics or history of intermittent diuretic usage for any reason over
             the previous 3 months.

          -  History of claustrophobia.

          -  Cachexia deemed by the investigator to be solely due to chemo or radiation treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M. Garcia, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System Seattle Division, Seattle, WA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2012</study_first_posted>
  <results_first_submitted>January 5, 2017</results_first_submitted>
  <results_first_submitted_qc>January 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2017</results_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>10 subjects were consented, 9 received drug or placebo, 5 completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Anamorelin HCl
Anamorelin HCl: 100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>Placebo
Placebo: Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Anamorelin HCl
Anamorelin HCl: 100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Placebo
Placebo: Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="48" upper_limit="72"/>
                    <measurement group_id="B2" value="58" lower_limit="56" upper_limit="73"/>
                    <measurement group_id="B3" value="57" lower_limit="48" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Body Potassium.</title>
        <time_frame>2 years</time_frame>
        <population>10 subjects were consented, 9 received drug or placebo, primary outcome measure is available for 6 subjects, 5 completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Anamorelin HCl
Anamorelin HCl: 100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Placebo
Placebo: Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Potassium.</title>
          <population>10 subjects were consented, 9 received drug or placebo, primary outcome measure is available for 6 subjects, 5 completed the study.</population>
          <units>percentage change from baseline</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" lower_limit="-7.58" upper_limit="3.39"/>
                    <measurement group_id="O2" value="-2.22" lower_limit="-29.58" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition as Measured by Densitometry.</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Strength as Measured by Grip Strength.</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight.</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life.</title>
        <description>Quality of life as assessed using the Assessment SpondyloArthritis (ASAS), EuroQol five dimensions questionnaire (EQ-5D) and FACIT-F, Patient Reported Outcome assessments</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Appetite.</title>
        <description>Appetite measured by a visual analogue scale and a food diary.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Energy Expenditure.</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Performance.</title>
        <description>Functional performance using stair-climbing power, 6-minute walk, tests of the major muscle groups and 24 hour physical activity levels</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition.</title>
        <description>Body composition as measured by Total body nitrogen and bioimpedance.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability.</title>
        <description>The safety and tolerability of Anamorelin HCl assessed through the number of participants with Adverse Events.</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Anamorelin HCl
Anamorelin HCl: 100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Placebo
Placebo: Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>neoplasm progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jose M Garcia MD, PhD, Clinician Investigator</name_or_title>
      <organization>Department of Veterans Affairs</organization>
      <phone>206-7642984</phone>
      <email>jose.garcia@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

